Hyperthermic Intraperitoneal Chemotherapy: A Holistic Investigation of Global Outputs with Bibliometric Analysis

Hyperthermic intraperitoneal administration of chemotherapy (HIPEC) targets microscopic residues remaining after complete cytoreduction.

We systematically presented the development process of the HIPEC treatment regimen, the most remarkable publications on this topic, the most productive countries, and the future of treatment in the coming years.

The source of our study was the Web of Science (WoS) database which included the Korean Journal Database, core collection index, Russian Science Citation Index, and Sci ELO citation index.

We reached a total of 3,343 publications by analyzing the WoS database using the keyword of "Hyperthermic intraperitoneal chemotherapy". When the citations of the documents written about HIPEC were evaluated, we found that the highest citation was made in 2019. Co-citation analysis showed that there were 27,724 authors investigating the issue of HIPEC. The most active university was determined as Wake Forest University, USA. Collaboration and citation collaboration was observed between Wake Forest University, the University of Pittsburgh, and the University of Texas. The intersection point of all researcher countries was the USA. While reviewing the articles on HIPEC, we also identified new trends and topics in this regard. Ovarian cancers, gastric cancers, and colorectal cancers were found to be the types of cancer that had the strongest relationship with HIPEC.

HIPEC therapies should be considered an area of research that has been studied, published, and cited by surgeons, oncologists, and pharmacologists interested in the treatment of tumors with peritoneal spread.